Latest Competition News

State Street Global Advisors announces significant fee reductions and rebranding for its SPDR Australian Bond ETFs, aligning with the iBoxx index series to enhance market positioning and investor appeal.

NSX Limited has entered a Scheme Implementation Deed with CNSX Markets Inc. for a full acquisition at a 59% premium, subject to shareholder and regulatory approvals. The deal aims to strengthen NSX’s market position and expand its product offerings.

Vitura Health’s joint venture Flora Holdings has acquired Heyday Medical Clinic, a leading medicinal cannabis provider, enhancing its national clinical network and patient access across Australia.

Domino’s Pizza Enterprises announces the departure of long-serving ANZ CEO Kerri Hayman in August 2025, with Greg Steenson appointed as the new Chief Operating Officer to lead the next growth phase.

Yari Minerals has completed the acquisition of the Rolleston South Coal Project in Queensland’s Bowen Basin, adding a substantial 78.9 million tonnes inferred coal resource and planning further drilling to expand it.

Anson Resources has negotiated a pioneering scaled royalty structure for its Green River Lithium Project in Utah, reducing the previous flat 5% rate to a sliding scale tied to lithium prices. This move enhances project viability and investment certainty amid evolving regulatory reforms.

Zinc of Ireland NL has kicked off its inaugural drilling campaign at the Mt Clere project in Western Australia, targeting the large and previously untested ‘Robin 21’ geophysical anomaly. This move revives interest in a site last partially explored by BHP nearly three decades ago.

Perenti’s underground mining arm, Barminco, has locked in a $500 million contract extension at the Agnew Gold Mine, reinforcing a decade-long partnership with Gold Fields and promising steady earnings.

Gentrack reported a solid 9.8% revenue increase to NZ$112 million in HY25, driven by recurring revenue growth and international expansion, while net profit after tax surged 34.7%. The company’s outlook remains optimistic as it targets FY25 revenue above NZ$230 million and deeper market penetration across Asia, Europe, and the Middle East.

Gentrack Group Limited reported a solid 9.8% revenue increase and a 34.7% jump in net profit for the first half of 2025, yet opted against paying an interim dividend.

Osteopore Limited has increased its capital raise by drawing down an additional A$500,000 on its Tranche 1 redeemable convertible notes, bringing total subscriptions to A$3.5 million. The funds will support ongoing operations and future growth initiatives.

Cynata Therapeutics confirms that the recent FDA orphan-drug exclusivity granted to Ryoncil® will not block approval of its CYP-001 therapy, highlighting key differences in drug composition and patient indications.